Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma

被引：1
|
作者：
Mistry, Kavita [1 ,2 ]
Zhao, Sophia [3 ]
Strohbehn, Ian [4 ]
Wang, Qiyu [4 ]
Hanna, Paul [4 ,5 ]
Strohbehn, Samuel [4 ]
Katz-Agranov, Nurit [4 ]
Sullivan, Ryan J. [6 ]
Sise, Meghan E. [4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[3] Analyt Now LLC, Brookline, MA USA
[4] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA
[5] Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI USA
[6] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷 / 06期
关键词：
METASTATIC MELANOMA; DOUBLE-BLIND; OPEN-LABEL; VEMURAFENIB; PHASE-3; MULTICENTER; DABRAFENIB; TRAMETINIB; PLACEBO; ENCORAFENIB;
D O I：
10.1093/ndt/gfae049
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
10.1093/ndt/gfae049 Video Watch the video of this contribution at https://academic.oup.com/ndt/pages/author_videos gfae049Media1 6348384678112
引用
收藏
页码：1040 / 1043
页数：4
相关论文
共 50 条
  • [31] Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
    Kuske, Marvin
    Westphal, Dana
    Wehner, Rebekka
    Schmitz, Marc
    Beissert, Stefan
    Praetorius, Christian
    Meier, Friedegund
    PHARMACOLOGICAL RESEARCH, 2018, 136 : 151 - 159
  • [32] Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient
    Nardin, Charlee
    Colas, Morgane
    Badoz, Marc
    Roche-Kubler, Blandine
    Meneveau, Nicolas
    Puzenat, Eve
    Aubin, Francois
    EUROPEAN HEART JOURNAL, 2017, 38 (27) : 2151 - 2151
  • [33] Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
    Wahid, Mohd
    Jawed, Arshad
    Mandal, Raju K.
    Dar, Sajad A.
    Akhter, Naseem
    Somvanshi, Pallavi
    Khan, Farah
    Lohani, Mohtashim
    Areeshi, Mohammed Y.
    Haque, Shafiul
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 84 - 88
  • [34] Immunotherapy vs BRAF and MEK inhibitors in the treatment of metastatic melanoma
    Casas Hidalgo, I.
    Nieto Gomez, P.
    Rodriguez Delgado, A.
    Alvarez Sanchez, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 376 - 376
  • [35] A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
    Ruiz, Emmanuelle M.
    Alhassan, Solomon A.
    Errami, Youssef
    Abd Elmageed, Zakaria Y.
    Fang, Jennifer S.
    Wang, Guangdi
    Brooks, Margaret A.
    Abi-Rached, Joe A.
    Kandil, Emad
    Zerfaoui, Mourad
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [36] Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma
    Eroglu, Zeynep
    Ozgun, Alpaslan
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (09): : 545 - 551
  • [37] Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma
    Dimitrios C. Ziogas
    Frosso Konstantinou
    Spyros Bouros
    Maria Theochari
    Helen Gogas
    American Journal of Clinical Dermatology, 2021, 22 : 301 - 314
  • [38] The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
    Julia Lai-Kwon
    Chloe Khoo
    Serigne Lo
    Donna Milne
    Mustafa Mohamed
    Jeanette Raleigh
    Kortnye Smith
    Karolina Lisy
    Shahneen Sandhu
    Michael Jefford
    Journal of Cancer Survivorship, 2019, 13 : 503 - 511
  • [39] The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
    Lai-Kwon, Julia
    Khoo, Chloe
    Lo, Serigne
    Milne, Donna
    Mohamed, Mustafa
    Raleigh, Jeanette
    Smith, Kortnye
    Lisy, Karolina
    Sandhu, Shahneen
    Jefford, Michael
    JOURNAL OF CANCER SURVIVORSHIP, 2019, 13 (04) : 503 - 511
  • [40] Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors.
    Samoylenko, Igor
    Kharkevich, Galina
    Petenko, Natalia N.
    Orlova, Kristina V.
    Sinelnikov, Igor
    Utyashev, Igor A.
    Vikhrova, Anastasia
    Markina, Irina
    Demidov, Lev V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345